Coya Therapeutics (COYA) vs TuHURA Biosciences (HURA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Coya Therapeutics (COYA) has outperformed TuHURA Biosciences (HURA) over the past year, losing 21.1% versus a loss of 24.0%. TuHURA Biosciences is the larger company by market cap ($124.9 million vs $116.1 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | COYA | HURA |
|---|---|---|
| Share price | $4.95 | $1.96 |
| Market cap | $116.12M | $124.90M |
| 1-day change | -0.80% | +1.55% |
| YTD return | -14.66% | +158.92% |
| 1-year return | -21.05% | -24.03% |
| 5-year return | — | -99.87% |
| EPS (TTM) | $-1.07 | $-0.54 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.75 | $3.43 |
| 52-week low | $3.71 | $0.41 |
| Distance from 52-week high | -36.13% | -42.86% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +207.27% | +310.20% |
| Average volume | 158.05K | 245.98K |
| Shares outstanding | 23.46M | 63.73M |
| Employees | 8 | 22 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Coya Therapeutics
COYA stock →Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary therapies to enhance the function of regulatory T cells (Tregs). Its candidate product pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.
Health Care · Biotechnology: Pharmaceutical Preparations · 8 employees
About TuHURA Biosciences
HURA stock →TuHURA Biosciences, Inc., a clinical stage immuno-oncology company, that develops novel technologies for the treatment of cancer immunotherapies. The company's lead product candidate includes IFx2.0, an innate immune agonist designed to overcome primary resistance to checkpoint inhibitors.
Health Care · Biotechnology: Pharmaceutical Preparations · 22 employees
COYA vs HURA FAQ
Which is bigger, Coya Therapeutics or TuHURA Biosciences?
TuHURA Biosciences (HURA) is larger, with a market capitalization of $124.90M compared with $116.12M for Coya Therapeutics (COYA).
Which stock has performed better over the past year, COYA or HURA?
COYA returned -21.05% over the past 12 months, compared with -24.03% for HURA (price return, excluding dividends). Past performance does not predict future results.
Are Coya Therapeutics and TuHURA Biosciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.